Faruqi & Faruqi, LLP Launches Investigation into Capricor Therapeutics for Investor Claims

Faruqi & Faruqi, LLP Conducts Investigation on Capricor Therapeutics

In a recent announcement on August 22, 2025, Faruqi & Faruqi, LLP, a prominent national securities law firm, revealed it is investigating potential claims against Capricor Therapeutics, Inc. (NASDAQ: CAPR). This investigation arises amid growing concerns about the company's communications regarding their lead cell therapy candidate for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD).

Faruqi & Faruqi's inquiry centers on allegations that Capricor and its executives may have violated federal securities laws by making misleading statements to investors. According to reports, the firm claims Capricor made overly optimistic assertions about its ability to secure a Biologics License Application (BLA) for the therapeutic product, deramiocel. Simultaneously, the company is accused of failing to disclose vital and adverse information regarding the safety and efficacy of deramiocel based on the Phase 2 HOPE-2 trial data.

In a stark turn of events, on July 11, 2025, Capricor issued a press release indicating it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA). The letter outlined that the application did not meet the required evidence of effectiveness and highlighted the necessity for additional clinical data. Consequently, this led to a significant drop in Capricor's stock price, plummeting from $11.40 per share on July 10, 2025, to $7.64 the following day.

Faruqi & Faruqi is reaching out to investors who purchased Capricor securities between October 9, 2024, and July 10, 2025, encouraging them to voice their concerns. Josh Wilson, a senior partner at the firm, has been at the forefront of this investigation, inviting investors who faced losses to contact him directly for a discussion regarding their legal options. Interested investors must act quickly, as the deadline to seek the position of lead plaintiff in the federal securities class action against Capricor is September 15, 2025.

“This investigation aims to ensure that the rights of investors are protected, and those affected receive the information and potential restitution they deserve,” Wilson stated. Investors hold the option to either move to serve as lead plaintiff through counsel or choose to remain absent members of the class. Regardless of their choice, all investors’ abilities to share in any recovery are unaffected.

Moreover, Faruqi & Faruqi encourages any individuals or former employees with information regarding Capricor's actions to reach out confidentially. The firm has a long-standing history of recovering hundreds of millions of dollars for its clients since its establishment in 1995. With offices strategically located in New York, Pennsylvania, California, and Georgia, the firm has been pivotal in numerous successful securities litigation cases.

As shareholders continue to navigate the legal landscape surrounding Capricor, the law firm's commitment to pursuing justice remains a cornerstone of its mission. The complexities of securities laws can often be daunting, yet firms like Faruqi & Faruqi stand ready to assist investors in protecting their rights and seeking compensation for potential losses.

For further details regarding the ongoing investigation and to stay updated on key developments, interested parties can visit Faruqi & Faruqi's website or follow them on social media platforms such as LinkedIn and Facebook. As the deadline approaches, the urgency for shareholders to inform themselves and take necessary actions only heightens the importance of this situation.

Contact Information:
To learn more about the Capricor Therapeutics class action, visit Faruqi & Faruqi or reach out to Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Attorney Advertising. The firm is dedicated to handling all communications with complete confidentiality, guaranteeing the protection of all clients' interests.